



JAK2

Essential Molecular Testing for Suspected Myeloproliferative Neoplasms

JAK2 mutations are among the most common molecular markers associated with myeloproliferative neoplasms (MPNs). Identification of JAK2 alterations can support diagnosis, guide additional testing, and help distinguish clonal hematologic disorders from reactive conditions.


Why Order JAK2 Testing

- Support MPN diagnosis
- Differentiate clonal from reactive blood count abnormalities
- Assist with WHO diagnostic criteria
- Guide additional molecular testing and clinical management
- Monitor disease burden when clinically indicated

When Should JAK2 Testing Be Considered:

Patients presenting with:

- Elevated hemoglobin or hematocrit
- Persistent thrombocytosis
- Unexplained leukocytosis
- Suspected Polycythemia Vera
- Suspected Essential Thrombocythemia
- Suspected Primary Myelofibrosis



Why EmeritusDX?

- Expert Hematopathology Consultation
- Comprehensive Molecular Diagnostics
- TAT: 5-7 days
- Integrated Testing Strategy with Reflex Options
- Direct Access to Board-Certified Hematopathologists
- CAP-Accredited
- CLIA-Certified

Targets Detected:

- JAK2 V617F
- JAK2 Exon 12-15 sequencing

